High-dose fenretinide in oral leukoplakia

Area of Science:

• Oncology
• Pharmacology
• Dermatology

Background:

• Low-dose fenretinide showed limited efficacy in retinoid-resistant oral leukoplakia.
• Insufficient serum drug levels may have contributed to the lack of activity.
• Higher doses were investigated to potentially enhance therapeutic effects.

Purpose of the Study:

• To evaluate if higher-dose fenretinide improves response rates in oral leukoplakia compared to previous low-dose studies.
• To assess the safety and tolerability of higher-dose fenretinide treatment.
• To correlate serum drug levels with clinical response.

Main Methods:

• A single-arm, phase II trial involving patients with oral leukoplakia.
• Fenretinide administered at 900 mg/m(2) twice daily for four 3-week cycles.
• Clinical responses and serum drug levels assessed at week 12; trial closed early due to futility.

Main Results:

• Only 20% of patients achieved a partial response, leading to early trial closure.
• Fenretinide was well-tolerated, with only one grade 3 adverse event (diarrhea).
• Mean serum fenretinide levels reached 0.122 +/- 0.093 micromol/L at week 12.

Conclusions:

• Higher-dose fenretinide did not demonstrate improved efficacy for oral leukoplakia compared to lower doses.
• In vitro studies suggested high-dose fenretinide may be less effective against oral leukoplakia cells than lower doses.
• Further investigation into fenretinide dosing or alternative treatments for oral leukoplakia is warranted.